William Daniel Purchases 10,000 Shares of Henry Schein (NASDAQ:HSIC) Stock

Henry Schein, Inc. (NASDAQ:HSIC) Director William Daniel bought 10,000 shares of Henry Schein stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Henry Schein Trading Up 0.1%

Shares of NASDAQ HSIC opened at $69.45 on Thursday. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $89.29. The stock has a market cap of $7.91 billion, a P/E ratio of 20.98, a price-to-earnings-growth ratio of 1.74 and a beta of 0.82. The firm has a 50-day moving average of $75.09 and a 200 day moving average of $75.21. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the prior year, the company earned $1.15 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts expect that Henry Schein, Inc. will post 5.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HSIC. Citigroup began coverage on Henry Schein in a research report on Wednesday, April 15th. They set a “buy” rating and a $100.00 price objective for the company. Robert W. Baird set a $97.00 target price on Henry Schein in a report on Wednesday, May 6th. Barrington Research set a $97.00 target price on Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Weiss Ratings restated a “hold (c+)” rating on shares of Henry Schein in a report on Monday, May 4th. Finally, Morgan Stanley reaffirmed an “underweight” rating and issued a $64.00 price target (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and an average target price of $86.83.

Hedge Funds Weigh In On Henry Schein

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein in the 2nd quarter worth $25,000. MUFG Securities EMEA plc bought a new position in shares of Henry Schein during the second quarter valued at $27,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Henry Schein during the fourth quarter valued at $30,000. Federated Hermes Inc. bought a new stake in Henry Schein in the 4th quarter worth about $32,000. Finally, Los Angeles Capital Management LLC bought a new position in Henry Schein during the 4th quarter valued at about $37,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.